JP2008505148A - Ｂ細胞リンパ腫の治療における放射線標識化抗ｃｄ２０抗体を使用する組合わせ治療 - Google Patents

Ｂ細胞リンパ腫の治療における放射線標識化抗ｃｄ２０抗体を使用する組合わせ治療 Download PDF

Info

Publication number
JP2008505148A
JP2008505148A JP2007519697A JP2007519697A JP2008505148A JP 2008505148 A JP2008505148 A JP 2008505148A JP 2007519697 A JP2007519697 A JP 2007519697A JP 2007519697 A JP2007519697 A JP 2007519697A JP 2008505148 A JP2008505148 A JP 2008505148A
Authority
JP
Japan
Prior art keywords
antibody
nhl
treatment
patients
chemotherapeutic regimen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007519697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008505148A5 (https=
Inventor
クラウゼ，ベルナー
カルムス，ヨアヒム
クールマン，イェンス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34972426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2008505148(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Publication of JP2008505148A publication Critical patent/JP2008505148A/ja
Publication of JP2008505148A5 publication Critical patent/JP2008505148A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007519697A 2004-07-09 2005-07-07 Ｂ細胞リンパ腫の治療における放射線標識化抗ｃｄ２０抗体を使用する組合わせ治療 Withdrawn JP2008505148A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58641404P 2004-07-09 2004-07-09
PCT/EP2005/007213 WO2006005477A1 (en) 2004-07-09 2005-07-07 Combination therapywith radiolabeled anti-cd20 antibody in the treatment of b-cell lymphoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014006916A Division JP6034314B2 (ja) 2004-07-09 2014-01-17 Ｂ細胞リンパ腫の治療における放射線標識化抗ｃｄ２０抗体を使用する組合わせ治療

Publications (2)

Publication Number Publication Date
JP2008505148A true JP2008505148A (ja) 2008-02-21
JP2008505148A5 JP2008505148A5 (https=) 2012-01-26

Family

ID=34972426

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007519697A Withdrawn JP2008505148A (ja) 2004-07-09 2005-07-07 Ｂ細胞リンパ腫の治療における放射線標識化抗ｃｄ２０抗体を使用する組合わせ治療
JP2014006916A Expired - Lifetime JP6034314B2 (ja) 2004-07-09 2014-01-17 Ｂ細胞リンパ腫の治療における放射線標識化抗ｃｄ２０抗体を使用する組合わせ治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014006916A Expired - Lifetime JP6034314B2 (ja) 2004-07-09 2014-01-17 Ｂ細胞リンパ腫の治療における放射線標識化抗ｃｄ２０抗体を使用する組合わせ治療

Country Status (13)

Country Link
US (2) US20060029543A1 (https=)
EP (1) EP1765399A1 (https=)
JP (2) JP2008505148A (https=)
KR (1) KR101250127B1 (https=)
AU (1) AU2005261923B2 (https=)
BR (1) BRPI0513007A (https=)
CA (1) CA2568526C (https=)
IL (1) IL179636A (https=)
MX (1) MX2007000327A (https=)
NO (1) NO344366B1 (https=)
RU (1) RU2394596C2 (https=)
WO (1) WO2006005477A1 (https=)
ZA (1) ZA200701158B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8061104B2 (en) 2005-05-20 2011-11-22 Valinge Innovation Ab Mechanical locking system for floor panels
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
KR20130009760A (ko) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Ｃｄ２０ 항체 및 이의 용도
US11055552B2 (en) * 2016-01-12 2021-07-06 Disney Enterprises, Inc. Systems and methods for detecting light signatures and performing actions in response thereto

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001010974A (ja) * 1992-11-13 2001-01-16 Idec Pharmaceuticals Corp Ｂ細胞リンパ腫の治療のためのヒトｂリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用
US20030206903A1 (en) * 1998-08-11 2003-11-06 Idec Pharmaceuticals Corporation Combination therapies for B-cell lynphomas comprising administration of anti-CD20 antibody

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
WO2000059473A1 (en) * 1999-04-01 2000-10-12 Inex Pharmaceuticals Corp. Compositions and methods for treating lymphoma
WO2001074388A1 (en) * 2000-03-31 2001-10-11 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
WO2003068821A2 (en) * 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
EP1567863A4 (en) 2002-11-22 2007-10-03 Nuvelo Inc THERAPY AND DIAGNOSTIC PROCEDURES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001010974A (ja) * 1992-11-13 2001-01-16 Idec Pharmaceuticals Corp Ｂ細胞リンパ腫の治療のためのヒトｂリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用
US20030206903A1 (en) * 1998-08-11 2003-11-06 Idec Pharmaceuticals Corporation Combination therapies for B-cell lynphomas comprising administration of anti-CD20 antibody

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6011046570; 設楽研也: '分子生物学的研究に立脚した新規治療法　『抗体工学の進歩と癌治療』' 医学のあゆみ Ｖｏｌ．１９９，Ｎｏ．９, 20011201, Ｐ．６６３-６６７ *
JPN6011046571; 飛内賢正: '特集　-造血器腫瘍の新しい分子標的療法-　『１　新規抗体療法の開発　（４）放射性同位元素標識抗ＣＤ２０抗' 血液・免疫・腫瘍 Ｖｏｌ．８，Ｎｏ．３, 20030715, Ｐ．２５１-２５６ *
JPN6012041416; Ｒａｍｂａｌｄｉ，Ａ．　ｅｔ　ａｌ．: 'Ｍｏｎｉｔｏｒｉｎｇ　ｏｆ　ｍｉｎｉｍａｌ　ｒｅｓｉｄｕａｌ　ｄｉｓｅａｓｅ　ａｆｔｅｒ　ＣＨＯＰ　ａｎｄ　ｒｉｔｕｘｉｍａｂ　ｉｎ　ｐｒｅｖｉｏｕｓｌｙ　ｕｎｔｒｅａｔｅｄ　ｐａｔｉｅｎｔｓ　ｗｉｔ' Ｂｌｏｏｄ Ｖｏｌ．９９，Ｎｏ．３, 20020201, Ｐ．８５６-８６２ *
JPN6012041420; 飛内賢正: '『Ｒａｄｉｏｉｍｍｕｎｏｔｈｅｒａｐｙ』-１３１Ｉあるいは９０Ｙを抱合したマウス型抗ＣＤ２０抗体によ' 医学のあゆみ Ｖｏｌ．２０２，Ｎｏ．１, 20020706, Ｐ．７５-８０ *

Also Published As

Publication number Publication date
AU2005261923A1 (en) 2006-01-19
RU2007104839A (ru) 2008-08-20
NO20070763L (no) 2007-02-08
IL179636A0 (en) 2007-05-15
BRPI0513007A (pt) 2008-04-22
RU2394596C2 (ru) 2010-07-20
US20060029543A1 (en) 2006-02-09
NO344366B1 (no) 2019-11-18
ZA200701158B (en) 2008-09-25
CA2568526C (en) 2015-11-03
EP1765399A1 (en) 2007-03-28
JP6034314B2 (ja) 2016-11-30
WO2006005477A1 (en) 2006-01-19
US20190112383A1 (en) 2019-04-18
AU2005261923B2 (en) 2010-11-18
MX2007000327A (es) 2007-03-12
CA2568526A1 (en) 2006-01-19
KR20070042527A (ko) 2007-04-23
IL179636A (en) 2013-09-30
KR101250127B1 (ko) 2013-04-02
JP2014080429A (ja) 2014-05-08

Similar Documents

Publication Publication Date Title
Geyer Jr et al. Survival with trastuzumab emtansine in residual HER2-positive breast cancer
RU2708374C2 (ru) Комбинированная терапия для лечения рака
JP2022536511A (ja) 癌の処置のための併用療法での活性化可能抗ｐｄｌ１抗体および抗ｃｔｌａ－４抗体の使用
JP2023516936A5 (https=)
JP6034314B2 (ja) Ｂ細胞リンパ腫の治療における放射線標識化抗ｃｄ２０抗体を使用する組合わせ治療
JP2004512262A5 (https=)
JP6241932B2 (ja) 腫瘍性疾患のための治療
JP2022523740A (ja) Ｒｏｒ１抗体イムノコンジュゲートによる癌の治療
Zeng et al. Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma
WO2014142220A1 (ja) 抗腫瘍剤
ES2328159T3 (es) Inmunoglobulinas anti-epcam.
TW202440171A (zh) 治療前列腺癌之方法
JP2006523664A5 (https=)
WO2021213523A1 (zh) 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途
Riva et al. Locoregional immunotherapy of human ovarian cancer: preliminary results
CN119677533A (zh) 用于治疗癌症的检查点抑制剂与溶瘤病毒的组合
Colleoni et al. Mitoxantrone in patients affected by hepatocellular carcinoma with unfavorable prognostic factors
Chen et al. Phase I clinical trial of targeted therapy using 131I-Hepama-1 mAb in patients with hepatocellular carcinoma
CN115814076A (zh) 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
Furman et al. Testicular relapse in children with acute nonlymphoblastic leukemia
Sayre et al. Extramedullary plasmacytoma: angiographic findings
CN115531531A (zh) 抗人vegf抗体和化疗联用在制备治疗结直肠癌药物中的用途
KR20260058844A (ko) 전립선암 치료를 위한 조합 요법
Ren et al. Adverse reaction of a combined treatment for unresectable liver cancer
HK1048945B (en) Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111202

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20111202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121106

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130917

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20150821